News

The multicenter, dose-escalation Phase I trial is designed to evaluate the safety and tolerability of ALRN-6924 as a single agent. ALRN-6924 is a potent and specific re-activator of

A total of 15 patients aged two to 18 years from two groups were included in this pediatric-specific extension trial. The first group included ten previously treatment-naïve pediatric

Johnson & Johnson subsidiary Janssen Research & Development has launched three new research platforms, which will focus on the areas, including disease prevention, disease interception, and microbiome. The

The US Food and Drug Administration (FDA) has already granted clearance for the company’s investigational new drug (IND) submission and Phase II trial associated with Boxaban oral capsule.

The company said that three hospitals in the Philippines are expected to join the Phase II trial. Philippines is the 19th country to approve the company’s Phase III

ADXS-HPV is Advaxis’s investigational Lm-LLO immunotherapy designed to treat human papillomavirus (HPV)-associated cancers, while epacadostat is Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. As part of the

The collaboration will support the development, expansion and commercialization of Voyager’s new CNS product pipeline. It will also include several gene therapy programs for Parkinson’s disease (PD), Friedreich’s

By using the company’s Biochronomer polymer-based drug delivery platform, HTX-011 releases the local anesthetic bupivacaine and the anti-inflammatory meloxicam over an extended period. The Phase I trial in

The submission is for treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily in patients with genotype 1 (GT1) HCV infection. The application is based on data from the Phase